The major challenge in the therapeutic applicability of oligonucleotide-based drugs is the development of efficient and safe delivery systems. The carriers should be non-toxic and stable in vivo, but interact with the target cells and release the loaded oligonucleotides intracellularly. We approached this challenge by developing a light-triggered liposomal delivery system for oligonucleotides based on a non-cationic and thermosensitive liposome with indocyanine green (ICG) as photosensitizer. The liposomes had efficient release properties, as 90% of the encapsulated oligonucleotides were released after 1-minute light exposure. Cell studies using an enhanced green fluorescent protein (EGFP)-based splicing assay with HeLa cells showed light-a...
For more than two decades, antisense oligonucleotides (ODNs) have been used to modulate gene express...
Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the list o...
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great...
The major challenge in the therapeutic applicability of oligonucleotide-based drugs is the developme...
The major challenge in the therapeutic applicability of oligonucleotide-based drugs is the developme...
The oligonucleotide therapeutics field has seen remarkable progress over the last few years with the...
Direct conjugation of photosensitizer to oligonucleotides allows spatial and temporal co-localizatio...
Light triggered drug delivery systems offer attractive possibilities for sophisticated therapy, prov...
There is mounting interest in developing antisense and siRNA oligonucleotides into therapeutic entit...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
In order to achieve a sustained pharmacological activity of oligonucleotides (ODNs) and avoid repeat...
Light-triggered drug delivery systems enable site-specific and time-controlled drug release. In prev...
For more than two decades, antisense oligonucleotides (ODNs) have been used to modulate gene express...
Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the list o...
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great...
The major challenge in the therapeutic applicability of oligonucleotide-based drugs is the developme...
The major challenge in the therapeutic applicability of oligonucleotide-based drugs is the developme...
The oligonucleotide therapeutics field has seen remarkable progress over the last few years with the...
Direct conjugation of photosensitizer to oligonucleotides allows spatial and temporal co-localizatio...
Light triggered drug delivery systems offer attractive possibilities for sophisticated therapy, prov...
There is mounting interest in developing antisense and siRNA oligonucleotides into therapeutic entit...
Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have been recogniz...
In order to achieve a sustained pharmacological activity of oligonucleotides (ODNs) and avoid repeat...
Light-triggered drug delivery systems enable site-specific and time-controlled drug release. In prev...
For more than two decades, antisense oligonucleotides (ODNs) have been used to modulate gene express...
Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the list o...
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great...